Official Title
A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure
Brief Summary

The purpose of this study is to test the effect of purified (acellular) amniotic fluid as a treatment for SARS CoV-2 (COVID19)-associated respiratory failure. Past use of human amniotic products (i.e., membrane and fluid) is FDA-approved for tissue injury and has been used to reduce inflammation and fibrosis in patients with a variety of medical conditions. The investigators hypothesize that using nebulized and/or intravenous purified (acellular) amniotic fluid will reduce both inflammation in patients hospitalized for in SARS CoV-2 (COVID19)-associated respiratory failure, potentially leading to a decrease in respiratory support.

SARS CoV-2 Infection

Biological: Human Amniotic Fluid

Administration of amniotic fluid in SARS-CoV-2 positive patients

Eligibility Criteria

Inclusion Criteria:

- 1. Age ≥18

- 2. Hospitalized and symptomatic (cough, fevers, SOB, or sputum production)

- 3. SARS CoV-2 laboratory positive obtained within 14 days of enrollment

Exclusion Criteria:

- 1. None

Eligibility Gender
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
United States

University of Utah Health
Salt Lake City, Utah, United States

Craig Selzman, MD, Principal Investigator
University of Utah

University of Utah
NCT Number
Amniotic fluid
Respiratory failure
Critical illness
MeSH Terms
Respiratory Insufficiency